Himmelfarb Health Sciences Library, The George Washington University

Health Sciences Research Commons
Radiology Faculty Publications

Radiology

11-1-2021

ACR Appropriateness Criteria® Staging and Follow-up of Primary
Vaginal Cancer.
Aoife Kilcoyne
Ravi V Gottumukkala
Stella K Kang
Esma A. Akin
Carlin Hauck

See next page for additional authors

Follow this and additional works at: https://hsrc.himmelfarb.gwu.edu/smhs_rad_facpubs
Part of the Radiology Commons

Authors
Aoife Kilcoyne, Ravi V Gottumukkala, Stella K Kang, Esma A. Akin, Carlin Hauck, Nicole M Hindman,
Chenchan Huang, Namita Khanna, Rajmohan Paspulati, Gaiane M Rauch, Tamer Said, Atul B Shinagare,
Erica B Stein, Aradhana M Venkatesan, and Katherine E Maturen

APPROPRIATE USE CRITERIA

ACR Appropriateness Criteria Staging
and Follow-up of Primary Vaginal Cancer
Expert Panel on GYN and OB Imaging: Aoife Kilcoyne, MD a , Ravi V. Gottumukkala, MD b,
Stella K. Kang, MD, MS c, Esma A. Akin, MD d, Carlin Hauck, MD e, Nicole M. Hindman, MD f,
Chenchan Huang, MD g, Namita Khanna, MD h, Rajmohan Paspulati, MD i,
Gaiane M. Rauch, MD, PhD j, Tamer Said, MD k, Atul B. Shinagare, MD l, Erica B. Stein, MD m,
Aradhana M. Venkatesan, MD n, Katherine E. Maturen, MD, MS o
Abstract
Primary vaginal cancer is rare, comprising 1% to 2% of gynecologic malignancies and 20% of all malignancies involving the vagina.
More frequently, the vagina is involved secondarily by direct invasion from malignancies originating in adjacent organs or by metastases
from other pelvic or extrapelvic primary malignancies. Data on the use of imaging in vaginal cancer are sparse. Insights are derived from
the study of imaging in cervical cancer and have reasonable generalizability to vaginal cancer due to similar tumor biology. Given the
trend toward deﬁnitive chemoradiation for both cancers in all but early stage lesions, principles of postchemoradiation tumor response
evaluation are largely analogous. Accordingly, many of the recommendations outlined here are informed by principles translated from
the literature on cervical cancer. For pretreatment assessment of local tumor burden and in the case of recurrent vaginal cancer, MRI is
the preferred imaging modality. PET/CT has demonstrated utility for the detection of nodal metastatic and unexpected distant metastatic disease.
The American College of Radiology Appropriateness Criteria are evidence-based guidelines for speciﬁc clinical conditions that are
reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current
medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness
Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of
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Disclaimer: The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of
speciﬁed medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment.
Generally, the complexity and severity of a patient’s clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for
evaluation of the patient’s condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this
document. The availability of equipment or personnel may inﬂuence the selection of appropriate imaging procedures or treatments. Imaging techniques classiﬁed as investigational by the FDA
have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any
speciﬁc radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.
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imaging and treatment procedures for speciﬁc clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion
may supplement the available evidence to recommend imaging or treatment.
Key Words: Appropriateness Criteria, Appropriate Use Criteria, AUC, Imaging, Recurrence, Staging, Vaginal carcinoma
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ACR Appropriateness Criteria Staging and Follow-up of Primary Vaginal Cancer. Variants 1 to 3 and Tables 1 and 2.

Variant 1. Vaginal cancer. Pretreatment staging. Initial imaging.
Procedure

Appropriateness Category

Relative Radiation Level

MRI pelvis without and with IV contrast

Usually Appropriate

O

CT abdomen and pelvis with IV contrast

Usually Appropriate

☢☢☢

FDG-PET/CT skull base to mid-thigh

Usually Appropriate

☢☢☢☢

MRI abdomen and pelvis without and with IV contrast

May Be Appropriate

O

MRI abdomen and pelvis without IV contrast

May Be Appropriate

O

MRI pelvis without IV contrast

May Be Appropriate

O

CT chest with IV contrast

May Be Appropriate

☢☢☢☢

CT chest without IV contrast

May Be Appropriate

☢☢☢☢

US abdomen and pelvis transabdominal

Usually Not Appropriate

O

US pelvis transvaginal

Usually Not Appropriate

O

Fluoroscopy contrast enema

Usually Not Appropriate

☢☢☢

Radiography intravenous urography

Usually Not Appropriate

☢☢☢

CT abdomen and pelvis without IV contrast

Usually Not Appropriate

☢☢☢

CT chest without and with IV contrast

Usually Not Appropriate

☢☢☢☢

CT abdomen and pelvis without and with IV contrast

Usually Not Appropriate

☢☢☢☢

Variant 2. Posttreatment evaluation of vaginal cancer. No suspected recurrence. Initial imaging.
Procedure

Appropriateness Category

Relative Radiation Level

MRI pelvis without and with IV contrast

Usually Appropriate

O

FDG-PET/CT skull base to mid-thigh

Usually Appropriate

☢☢☢☢

MRI abdomen and pelvis without and with IV contrast

May Be Appropriate

O

MRI abdomen and pelvis without IV contrast

May Be Appropriate

O

MRI pelvis without IV contrast

May Be Appropriate

O

CT abdomen and pelvis with IV contrast

May Be Appropriate

☢☢☢

CT chest with IV contrast

May Be Appropriate

☢☢☢☢

CT chest without IV contrast

May Be Appropriate

☢☢☢☢

US abdomen and pelvis transabdominal

Usually Not Appropriate

O

US pelvis transvaginal

Usually Not Appropriate

O

Fluoroscopy contrast enema

Usually Not Appropriate

☢☢☢

Radiography intravenous urography

Usually Not Appropriate

☢☢☢

CT abdomen and pelvis without IV contrast

Usually Not Appropriate

☢☢☢

CT chest without and with IV contrast

Usually Not Appropriate

☢☢☢☢

CT abdomen and pelvis without and with IV contrast

Usually Not Appropriate

☢☢☢☢
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Variant 3. Vaginal cancer. Suspected or known recurrence. Evaluate extent of disease. Initial imaging.
Procedure

Appropriateness Category

Relative Radiation Level

MRI pelvis without and with IV contrast

Usually Appropriate

O

CT abdomen and pelvis with IV contrast

Usually Appropriate

☢☢☢

CT chest with IV contrast

Usually Appropriate

☢☢☢☢

FDG-PET/CT skull base to mid-thigh

Usually Appropriate

☢☢☢☢

MRI abdomen and pelvis without and with IV
contrast
MRI abdomen and pelvis without IV contrast

May Be Appropriate

O

May Be Appropriate

O

MRI pelvis without IV contrast

May Be Appropriate

O

CT chest without IV contrast

May Be Appropriate

☢☢☢☢

US abdomen and pelvis transabdominal

Usually Not Appropriate

O

US pelvis transvaginal

Usually Not Appropriate

O

Fluoroscopy contrast enema

Usually Not Appropriate

☢☢☢

Radiography intravenous urography

Usually Not Appropriate

☢☢☢

CT abdomen and pelvis without IV contrast

Usually Not Appropriate

☢☢☢

CT chest without and with IV contrast

Usually Not Appropriate

☢☢☢☢

CT abdomen and pelvis without and with IV
contrast

Usually Not Appropriate

☢☢☢☢

Table 1. Appropriateness category names and deﬁnitions
Appropriateness Category
Name

Appropriateness
Rating

Usually Appropriate

7, 8, or 9

May Be Appropriate

4, 5, or 6

May Be Appropriate
(Disagreement)

5

Usually Not Appropriate

1, 2, or 3
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Appropriateness Category Deﬁnition
The imaging procedure or treatment is indicated in the speciﬁed
clinical scenarios at a favorable risk-beneﬁt ratio for patients.
The imaging procedure or treatment may be indicated in the
speciﬁed clinical scenarios as an alternative to imaging
procedures or treatments with a more favorable risk-beneﬁt ratio,
or the risk-beneﬁt ratio for patients is equivocal.
The individual ratings are too dispersed from the panel median. The
different label provides transparency regarding the panel’s
recommendation. “May be appropriate” is the rating category
and a rating of 5 is assigned.
The imaging procedure or treatment is unlikely to be indicated in the
speciﬁed clinical scenarios, or the risk-beneﬁt ratio for patients is
likely to be unfavorable.
Journal of the American College of Radiology
Volume 18 n Number 11S n November 2021

Table 2. Relative radiation level designations
RRL

Adult Effective Dose Estimate Range (mSv)

Pediatric Effective Dose Estimate Range (mSv)

O

0

0

☢

<0.1

<0.03

☢☢

0.1-1

0.03-0.3

☢☢☢

1-10

0.3-3

☢☢☢☢

10-30

3-10

☢☢☢☢☢

30-100

10-30

Note: Relative radiation level (RRL) assignments for some of the examinations cannot be made, because the actual patient doses in these
procedures vary as a function of a number of factors (eg, region of the body exposed to ionizing radiation, the imaging guidance that is
used). The RRLs for these examinations are designated as “varies.”

SUMMARY OF LITERATURE REVIEW
Introduction/Background
Primary vaginal cancer is rare, comprising 1% to 2% of
gynecologic malignancies and 20% of all malignancies
involving the vagina [1,2]. More frequently, the vagina is
involved secondarily either by direct invasion from
malignancies originating in adjacent organs, most
commonly the cervix or vulva, or by metastases from
other pelvic or extrapelvic primary malignancies [1,2].
Additionally, any vaginal tumor involving the cervix or
vulva, whether or not the lesion is centered in the
vagina, is classiﬁed by the International Federation of
Gynecology and Obstetrics (FIGO) system as a primary
cervical or vulvar cancer, respectively. Squamous cell
carcinoma is the most common underlying histology in
primary vaginal cancer, representing 80% to 90% of
primary vaginal cancer [3], and occurs most frequently
in postmenopausal women, with adenocarcinoma
representing around 5% to 10% of cases and even rarer
histologies such as sarcoma, melanoma, and lymphoma
accounting for the remainder [1,2].
Primary vaginal cancer is staged according to two
systems, FIGO and the American Joint Committee on
Cancer (AJCC). FIGO stipulates a clinical staging
paradigm, whereby features derived from bimanual and/
or rectovaginal examination, cystoscopy, proctoscopy,
and radiography are permissible for incorporation into
staging [4]. Although FIGO encourages the use of
advanced imaging modalities such as CT, MRI, and
PET to guide management, information derived from
these examinations does not alter the formal clinical
FIGO stage [4]. Given the rarity of primary vaginal
cancer, treatment principles are derived from
retrospective data in addition to extrapolation from
more established management paradigms for cervical

and anal squamous cell cancers. Surgical management
for vaginal cancer is limited primarily to small (<2
cm) early stage lesions, with larger lesions posing
greater difﬁcultly for achieving negative surgical
margins. Although surgical options exist for locally
advanced disease, they often involve a degree of pelvic
exenteration
and
therefore
confer
substantial
morbidity. For this reason, the management paradigm
for locally advanced disease has largely trended toward
deﬁnitive
radiation
therapy
with
concurrent
chemotherapy [1,5]. Though data on the use of
imaging in vaginal cancer are sparse, insights derived
from the study of imaging in cervical cancer have
reasonable generalizability to vaginal cancer because of
similar tumor biology. Moreover, given the trend
toward deﬁnitive chemoradiation for both cancers in
all
but
early
stage
lesions,
principles
of
postchemoradiation tumor response evaluation are
largely analogous. Accordingly, many of the
recommendations outlined in this document are
informed by principles translated from the literature
on cervical cancer.

Special Imaging Considerations
Radiation Therapy Planning. CT and MRI are fundamental to radiation therapy planning for gynecologic malignancies, during which precise delineation of the target
volume and at-risk organs optimizes tumor control while
minimizing treatment-related toxicity [6,7]. The evolving
trend of adaptive image-guided external beam radiation
therapy and brachytherapy for cervical and vaginal cancer—
whereby target volumes and dose curves are dynamically
modiﬁed over the course of therapy based on changes in
tumor volume—has further expanded the role of advanced
imaging [8,9]. The use of imaging in initial and adaptive
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radiation planning for vaginal cancer is not speciﬁcally
addressed in this document, and analogous principles for
cervical cancer are covered in extensive detail elsewhere [6].

Initial Imaging Deﬁnition
Initial imaging is deﬁned as imaging at the beginning of the
care episode for the medical condition deﬁned by the
variant. More than one procedure can be considered usually
appropriate in the initial imaging evaluation when:
n

There are procedures that are equivalent alternatives (ie,
only one procedure will be ordered to provide the clinical
information to effectively manage the patient’s care)
OR

n

There are complementary procedures (ie, more than one
procedure is ordered as a set or simultaneously in which
each procedure provides unique clinical information to
effectively manage the patient’s care).

DISCUSSION OF PROCEDURES BY VARIANT
Variant 1: Vaginal cancer. Pretreatment
staging. Initial imaging
Although the 2009 FIGO staging system for vaginal cancer
indicates that ﬁndings on advanced imaging (CT, MRI,
PET/CT) should not modify stage designation [4], such
imaging ﬁndings are routinely employed in clinical
practice to prognosticate and guide management decisions
in patients with vaginal cancer. Recent updates to the
FIGO staging system for cervical cancer, which
incorporate advanced imaging results into staging [10],
reﬂect the wide recognition that cross-sectional imaging
provides actionable staging information not readily obtained
by physical examination or conventional radiography.
Moreover, the increasing use of deﬁnitive radiotherapy
across all stages of vaginal cancer obligates the incorporation
of advanced imaging into pretreatment evaluation, because
it is essential for treatment planning.
The rationale for optimizing staging accuracy in vaginal
cancer, in part via the inclusion of cross-sectional imaging, is
multifold. First, accurate initial staging is fundamental to
prognostication [11], facilitating incorporation of
expectations of treatment efﬁcacy into goals of care.
Second, proper initial staging permits selection of the
most appropriate treatment based on extent of disease.
Regarding local extent, for vaginal lesions deemed likely
conﬁned to the vaginal wall (stage I) based on clinical
examination, exclusion of extravaginal invasion with
further testing is essential for ensuring that planned
deﬁnitive surgery is likely to achieve a disease-free margin
or that a radiation ﬁeld properly incorporates the tumor
S446

volume. Regional nodal metastases include pelvic nodal
metastases, which are primarily detected with cross-sectional
imaging, and inguinal nodes (in lower vaginal cancers), a
subset of which can be identiﬁed on clinical examination.
Pretreatment knowledge of suspicious nodes may impact the
decision to pursue surgery versus radiation. In addition, the
distribution of suspicious nodes has the potential to inﬂuence radiation-speciﬁc factors such as ﬁeld and dose planning, including possible node-directed boost doses as
employed in cervical cancer [12]. Regarding distant
metastases, detection of extraregional nodal or solid organ
lesions can obviate unnecessarily morbid radical pelvic
surgery and instead direct care toward palliative regimens
or radiotherapy with an extended ﬁeld. Finally, the ability
to accurately stage noninvasively can avoid the need for
invasive staging procedures such as cystoscopy (for bladder
mucosal invasion) and proctoscopy (for rectal mucosal
invasion), both of which are historical components of the
FIGO clinical staging system [1].

CT Chest. Although thoracic metastases are known to
occur in vaginal cancer, no studies speciﬁcally address their
incidence or the incremental value of chest CT for initial
staging. Pulmonary metastases have been studied to a
limited degree in cervical cancer, occurring in approximately
5% to 10% of patients at diagnosis [13,14]. Pulmonary
metastases appear to occur slightly more frequently as a
site of recurrent disease, with one large study of recurrent
cervical cancer indicating an overall incidence of 13%, and
the lungs representing the only site of recurrence in 6% of
cases [15]. In studies evaluating pulmonary metastases
from cervical cancer, chest CT was the most frequent
diagnostic modality employed, with the vast majority of
patients asymptomatic at the time of imaging [16,17].
These ﬁndings support the use of chest CT with or
without intravenous (IV) contrast in the early
posttreatment evaluation of cervical cancer, as endorsed by
the National Comprehensive Cancer Network (NCCN)
guidelines, and suggest that a similar strategy would be
useful for vaginal cancer.
CT Abdomen and Pelvis. Data on the diagnostic performance of CT in primary vaginal cancer staging are very
limited. A small retrospective study evaluating ﬂuorine-182-ﬂuoro-2-deoxy-D-glucose (FDG)-PET/CT in 23 patients
with primary vaginal cancer found that CT and FDG-PET
detected pelvic nodal metastases in 17% (4 of 23) and 35%
(8 of 23) of patients, respectively, suggesting inferior sensitivity of CT alone [18].
CT has been studied more extensively in cervical cancer
staging, with available data comparing CT to MRI for local
staging and CT (with or without IV contrast) to PET for
regional and distant staging. For local staging, the ACRIN
Journal of the American College of Radiology
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6651 study showed that CT and MRI had sensitivity of
42% and 53%, respectively, and speciﬁcity of 82% and
75%, respectively, for classifying disease as stage IIB (parametrial invasion) or higher, with none of these differences
reaching statistical signiﬁcance [19]. However, a more recent
meta-analysis suggested improved performance of MRI for
parametrial invasion with modern hardware (sensitivity
76%, speciﬁcity 94%), particularly when the ﬁeld strength
was 3T and diffusion-weighted imaging was included [20],
whereas a recent study of multidetector CT showed only
50% sensitivity for parametrial invasion [21].
Although older literature suggested lower sensitivity of
CT compared with FDG-PET/CT for nodal metastases
[22], the more recent ACRIN 6671/Gynecology Oncology
Group (GOG) 0233 trial demonstrated a more modest
difference in sensitivity for abdominal nodes (42% versus
50%, respectively) [23]. Likewise, in a recent metaanalysis, CT had only modestly lower area under the
curve (AUC) (0.83) compared with PET/CT (0.90) for
detection of nodal metastases from cervical cancer [24]. For
distant metastases from cervical cancer, CT is inferior in the
detection of osseous metastases (sensitivity 66%) compared
with FDG-PET/CT (sensitivity 96%) [25].
These ﬁndings, if applied to vaginal cancer, suggest that
modern multidetector CT abdomen and pelvis is a reasonable staging tool for regional and distant metastases,
although is likely inferior to MRI for local staging, modestly
inferior to FDG-PET/CT for nodal metastases, and inferior
to FDG-PET/CT for osseous metastases. The use of IV
contrast is strongly encouraged when possible, because the
improved tissue contrast likely beneﬁts primary tumor
evaluation, delineation of lymph nodes from adjacent vessels, and detection of hepatic metastases. No studies have
speciﬁcally evaluated the performance of CT of the
abdomen and pelvis without IV contrast for vaginal cancer
staging.

FDG-PET/CT Skull Base to Mid-Thigh. Data
regarding the diagnostic performance of PET/CT for initial
staging in patients with vaginal cancer are limited. Lamoreaux et al [18], in a prospective study, evaluated the
comparative performance of PET versus CT in 23 patients
with primary vaginal cancer prior to treatment. PET
identiﬁed suspicious pelvic and/or groin lymph nodes in
35% (8 of 23) of patients, whereas CT did so in only
17% (4 of 23) of patients, although a pathologic reference
standard was present in only two sampled groin nodes.
No patient had extrapelvic nodal or distant disease,
limiting the applicability of this study to metastases
outside of the pelvis.
A study of 50 patients (83 imaging examinations)
enrolled in the National Oncologic PET Registry, which

included 29 FDG-PET/CT studies from patients with
known or suspected primary or recurrent vaginal cancer,
found that FDG-PET/CT changed the treating physician’s
prognostic impression in 45% (13 of 29) of cases [26].
Additionally, a change in patient management occurred
following 36% (30 of 83) of all FDG-PET/CT studies,
including the 53 studies in vulvar cancer patients. However,
conclusions regarding comparative performance of FDGPET/CT versus conventional imaging (CT or MRI) on
the basis of this study are limited, because only a minority of
cases had comparison to conventional imaging (CT or
MRI), and a majority of the lesions compared were incidental and not pertinent to the primary malignancy.
Although data are limited for primary vaginal cancer
staging, a growing body of literature supports the role of
FDG-PET/CT in the initial staging of cervical cancer.
Prospective data from the ACRIN 6671/GOG 0233 trial
suggested, with borderline statistical signiﬁcance, that FDGPET/CT is more sensitive than CT alone for extrapelvic
nodal metastases in cervical cancer (50% versus 42%,
respectively), with similar speciﬁcity (85% versus 89%,
respectively) [23], supporting prior retrospective data [22].
FDG-PET/CT is also more sensitive than conventional
CT for osseous metastases [25], with sensitivity and
speciﬁcity of 55% and 98%, respectively, for all distant
metastases [13]. Accordingly, the NCCN guidelines
endorse preference for whole-body FDG-PET/CT over
conventional CT for initial staging of all cervical cancer
designated stage II and above, with either FDG-PET/CT or
conventional CT recommended in stage I disease [27].

Fluoroscopy Contrast Enema. There is no relevant
literature regarding the use of ﬂuoroscopic contrast enema in
the modern imaging workup of vaginal cancer, and its use
has largely been replaced by cross-sectional imaging
techniques.
MRI Pelvis. Because of the rarity of vaginal cancer, the
primary data regarding the use of MRI in initial staging of
vaginal cancer are sparse. Taylor et al [28] retrospectively
evaluated pelvic MRI for initial staging in 25 patients with
primary vaginal cancer spanning all disease stages. MRI
depicted the primary tumor in 96% (24 of 25) of
patients, demonstrating hyperintense signal compared to
muscle on T2-weighted images, and enabled assignment
of a radiologic disease stage based on adaptation of FIGO
clinical staging criteria. Because 80% (20 of 25) of patients
received either radiation or palliative therapy, pathologic
conﬁrmation of imaging ﬁndings could be obtained in only
20% (5 of 25) of cases. Of these cases, MRI stage was
concordant with pathologic stage in 40% (2 of 5) of the
cases. More recent data in cervical cancer patients support
the use of MRI for initial staging, with a meta-analysis
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suggesting high sensitivity (76%) and speciﬁcity (94%) of
MRI for parametrial invasion [20].
Although MRI readily depicts lymph nodes, it has
constraints similar to CT with regard to the limited sensitivity and speciﬁcity of size and morphologic criteria. No
study has speciﬁcally evaluated the performance of MRI for
pretreatment nodal staging in vaginal cancer. However, data
from mixed cohorts of patients with recurrence of cervical,
vaginal, and other gynecologic cancers have suggested superior sensitivity of FDG-PET/CT for pelvic nodal metastases compared with pelvic MRI and CT [29,30].
The use of IV contrast may improve tissue characterization but is not considered essential, with variable inclusion in published protocols for evaluation of vaginal [28,31]
and cervical cancer [7,32-34]. No study has speciﬁcally
compared the incremental utility of contrast-enhanced sequences over T2-weighted sequences for pelvic MRI in this
context. Regarding the use of vaginal gel in MRI of the
pelvis, there is insufﬁcient primary data in the literature to
support its routine use.

MRI Abdomen and Pelvis. Because of the rarity of vaginal
cancer, the primary data regarding the use of MRI in initial
staging of vaginal cancer are sparse. Taylor et al [28]
retrospectively evaluated pelvic MRI for initial staging in 25
patients with primary vaginal cancer spanning all disease
stages. MRI depicted the primary tumor in 96% (24 of 25)
of patients, demonstrating hyperintense signal compared to
muscle on T2-weighted images, and enabled assignment of a
radiologic disease stage based on adaptation of FIGO clinical
staging criteria. Because 80% (20 of 25) of patients received
either radiation or palliative therapy, pathologic conﬁrmation
of imaging ﬁndings could be obtained in only 20% (5 of 25) of
cases. Of these cases, MRI stage was concordant with pathologic stage in 40% (2 of 5). More recent data in cervical cancer
patients support the use of MRI for initial staging, with a metaanalysis suggesting high sensitivity (76%) and speciﬁcity (94%)
of MRI for parametrial invasion [20].
Although MRI readily depicts lymph nodes, it has
constraints similar to CT with regard to the limited sensitivity and speciﬁcity of size and morphologic criteria. No
study has speciﬁcally evaluated the performance of MRI for
pretreatment nodal staging in vaginal cancer. However, data
from mixed cohorts of patients with recurrence of cervical,
vaginal, and other gynecologic cancers have suggested superior sensitivity of FDG-PET/CT for pelvic nodal metastases compared with pelvic MRI and CT [29,30].
If MRI of the abdomen and pelvis is used in place of CT
of the abdomen and pelvis, the addition of chest CT is
encouraged to evaluate for pulmonary metastases. The use of
IV contrast may improve tissue characterization and is
particularly beneﬁcial when MRI of the abdomen is
S448

included, because it improves detection of hepatic
metastases.

Radiography Intravenous Urography. There is no
relevant literature regarding the use of radiographic IV
urography in the modern imaging workup of vaginal cancer,
and its use has largely been replaced by cross-sectional imaging techniques.
US Pelvis Transvaginal. Transvaginal (TV) pelvic ultrasound (US) has no established role in the initial staging of
primary vaginal cancer, and no study to date has evaluated
its utility in this setting. Multiple prospective studies have
explored the role of TVUS in cervical cancer staging with
variable results but suggestion of a similar general range of
accuracy for detecting parametrial invasion compared to
MRI [35,36]. Other retrospective data have suggested
agreement between 3-D TVUS and MRI ranging from
moderate (k ¼ 0.51) to good (k ¼ 0.60) for parametrial
invasion, with very good (k ¼ 0.84) agreement for bladder
invasion [37,38]. Although these ﬁndings suggest some
potential utility of 3-D TVUS for cervical cancer staging,
the current NCCN guidelines do not endorse its use for
staging. At present, the generalizability of these studies to
vaginal cancer staging remains limited, although these data
along with emerging techniques such as sonovaginography—the instillation of vaginal gel during TVUS to
improve vaginal wall visualization—may prompt future
investigation into the role of potential TVUS for local
staging in vaginal cancer. For pelvic node evaluation, TVUS
has limited utility [39].
US Abdomen and Pelvis Transabdominal. There is no
relevant literature regarding the role of transabdominal
abdominopelvic (TA) US in vaginal cancer staging. TAUS is
inferior for visualizing the female genital tract compared
with TVUS, and neither technique has a role in the evaluation of regional or distant disease.

Variant 2: Posttreatment evaluation of
vaginal cancer. No suspected recurrence.
Initial imaging
As the use of deﬁnitive chemoradiation for the treatment of
primary vaginal cancer has grown, so too has the role of
cross-imaging for assessment of treatment response. In
contrast to extirpative surgery, in which pathologic margin
assessment can conﬁrm removal of viable tumor, evaluation
for tumor eradication following chemoradiation relies in
part on imaging assessment. Much of the support for the
value of early posttreatment imaging in primary vaginal
cancer is extrapolated from the large body of literature on
cervical cancer, for which the treatment paradigm and
endpoints are analogous. Early posttreatment imaging is
Journal of the American College of Radiology
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performed most commonly following a period of approximately 3 to 6 months after the completion of chemoradiation. Some centers also image during therapy for early
response assessment and/or adaptive radiation planning [7].
The goals of early posttreatment imaging are multiple.
First, imaging response after chemoradiation is a potent predictor of oncologic outcome, therefore providing crucial
prognostic data [40-42]. Second, the degree of imaging
response directly informs therapeutic decision-making,
because persistent or progressive disease following chemoradiation requires salvage therapy [40]. For persistent pelvic
disease, options include salvage radical surgery or less
commonly reirradiation. Detection of new distant disease
following initial treatment obviates curative surgery and may
direct therapy toward chemotherapeutic and/or palliative
options. Finally, the degree of response can inﬂuence the
frequency of subsequent surveillance, with complete
response enabling more conservative follow-up testing [42].
Following complete response, there is no formally
established role for routine surveillance imaging in asymptomatic patients treated for vaginal cancer nor has a role
been established for cervical cancer. Guidelines generally
advocate for routine clinical examination for surveillance in
asymptomatic patients, with imaging suggested in the
setting of symptoms or abnormal physical examination
ﬁndings [43].

CT Chest. Although thoracic metastases are known to
occur in vaginal cancer, no studies speciﬁcally address their
incidence or the incremental value of chest CT in early
posttreatment evaluation. Pulmonary metastases have been
studied to a limited degree in cervical cancer, occurring in
approximately 5% to 10% of patients at diagnosis [13,14].
Pulmonary metastases appear to occur slightly more
frequently as a site of recurrent disease, with one large
study of recurrent cervical cancer indicating an overall
incidence of 13%, and the lungs representing the only site
of recurrence in 6% of cases [15]. Moreover, the lungs
can uncommonly represent a site of distant disease that
newly arises following deﬁnitive chemoradiation for disease
that was initially locoregional [41]. In studies evaluating
pulmonary metastases from cervical cancer, chest CT was
the most frequent diagnostic modality employed, with the
vast majority of patients asymptomatic at the time of
imaging [16,17]. These ﬁndings support the use of chest
CT with or without IV contrast in the early posttreatment
evaluation of cervical cancer, as endorsed by the NCCN
guidelines, and suggest that a similar strategy would be
useful for vaginal cancer.
CT Abdomen and Pelvis. For detection of residual primary tumor after chemoradiation, CT alone is likely inferior
compared with FDG-PET/CT and pelvic MRI based on

extrapolation from data on comparative imaging performance in the pretreatment evaluation of cervical cancer
[21,44]. CT lacks the tissue contrast of MRI and the
metabolic data of FDG-PET, both of which are useful in
deciphering posttreatment changes from residual disease.
Because CT relies primarily on size criteria for nodal evaluation, it has limitations similar to MRI with respect to
sensitivity and speciﬁcity for nodal metastases. Therefore,
although CT may depict size regression of nodal metastases
following therapy, it is likely at least modestly inferior for
detecting new or residual disease in subcentimeter lymph
nodes compared with FDG-PET/CT [22,23,29,30].
CT of the abdomen and pelvis is not commonly performed
in the absence of chest CT, given that the lungs are a potential
site of distant disease that may newly arise in patients who have
undergone deﬁnitive chemoradiation for disease that was
initially locoregional [41]. Importantly, CT alone is inferior to
FDG/PET-CT for evaluation of distant disease in the bones
[25] and modestly inferior for nodal assessment [23,41].
The use of IV contrast is strongly encouraged when
possible, because the improved tissue contrast likely beneﬁts
primary tumor evaluation, delineation of lymph nodes from
adjacent vessels, and detection of hepatic metastases. No
studies have speciﬁcally assessed the performance of CT of
the abdomen and pelvis without IV contrast for posttreatment evaluation of primary vaginal cancer.

FDG-PET/CT Skull Base to Mid-Thigh. Although data
in primary vaginal cancer patients are limited, studies substantiating its treatment response assessment role in cervical
cancer are numerous. In one prospective study in cervical
cancer patients treated with deﬁnitive chemoradiation, FDGPET/CT responses classiﬁed as complete metabolic response
(absence of abnormal uptake at prior sites of disease), partial
metabolic response and progressive disease at a mean of 3
months after therapy correlated closely with prognosis, with
3-year progression-free survival of 78%, 33%, and 0%,
respectively [40]. In another prospective study, 9% (5 of 55)
of patients developed new distant disease at the time of a
posttreatment FDG-PET/CT scan, underscoring the value
of whole-body imaging rather than pelvic-only imaging at the
time of response evaluation [41]. Accordingly, the NCCN
guidelines for cervical cancer recommend whole-body
FDG-PET/CT at 3 to 6 months after completion of deﬁnitive therapy for disease stages II to IV, because it directly
informs prognosis, therapy, and intensity of surveillance [27].
Fluoroscopy Contrast Enema. There is no relevant
literature regarding the use of ﬂuoroscopic contrast enema in
the modern imaging workup of vaginal cancer, and its use
has largely been replaced by cross-sectional imaging
techniques.
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MRI Pelvis. Although no study has speciﬁcally evaluated
pelvic MRI for treatment response assessment in vaginal
cancer patients, multiple studies support its potential value
in cervical cancer to which analogous principles apply.
Following successful therapy with chemoradiation, the
initially intermediate to high-signal-intensity tumor on T2weighted images decreases in both size and signal intensity,
with eventual conversion to low-signal-intensity ﬁbrotic
tissue [7,31]. However, the main limitation of MRI in the
very early posttreatment period (<2 months after
completion) is its difﬁculty distinguishing early
postradiation change from residual tumor, both of which
can demonstrate intermediate- to high-signal T2-weighted
intensity and avid gadolinium enhancement [33,34].
One retrospective study evaluating pelvic MRI at a median of 5 weeks after completion of chemoradiation for cervical cancer found that 37% (16 of 44) of MRI examinations
were considered indeterminate for discriminating residual
disease and ﬁbrosis [34]. Despite diagnostic conﬁdence in the
remainder of cases, sensitivity and speciﬁcity for residual
disease were 80% and 55%, respectively, indicating a high
false-positive rate because of posttreatment change. A more
recent retrospective study in cervical cancer patients found
better performance of pelvic MRI at a later postchemoradiation time point (median 9 weeks) with strict
objective diagnostic criteria, achieving sensitivity and speciﬁcity of 91% and 85%, respectively, for residual disease [33].
Therefore, for cervical cancer, the suggested time interval for
determining posttherapy treatment response with pelvic MRI
is 3 to 6 months after completion of therapy [27], although
earlier imaging is sometimes used for interim assessment of
tumor regression for prognostication and/or adaptive
radiation planning. Because MRI relies primarily on size
criteria for nodal evaluation, it has limitations similar to CT
with respect to sensitivity and speciﬁcity for nodal
metastases. Therefore, although MRI may depict size
regression of nodal metastases following therapy, it is likely
at least modestly inferior for detecting new or residual
disease in subcentimeter lymph nodes compared to FDGPET/CT [22,23,29,30].
The use of IV contrast may improve tissue characterization but is not considered essential, with variable inclusion in published protocols for evaluation of vaginal [28,31]
and cervical cancer [7,32-34]. No study has speciﬁcally
compared the incremental utility of gadolinium-enhanced
sequences over T2-weighted sequences for pelvic MRI in
this context. Regarding the use of vaginal gel in MRI of the
pelvis, there is insufﬁcient primary data in the literature to
support its routine use.
MRI Abdomen and Pelvis. MRI of the abdomen and
pelvis can be considered in the early posttreatment
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evaluation of primary vaginal cancer, although its main value
is in the utility of pelvic MRI for primary tumor response
assessment. MRI of the abdomen is not commonly
included, given the availability of whole-body FDG-PET/
CT or CT of the chest, abdomen, and pelvis for evaluation
of distant disease. Although no study has speciﬁcally evaluated pelvic MRI for treatment response assessment in
vaginal cancer patients, multiple studies support its potential
value in cervical cancer to which analogous principles apply.
Following successful therapy with chemoradiation, the
initially intermediate- to high-signal-intensity tumor on T2weighted images decreases in both size and signal intensity,
with eventual conversion to low-signal-intensity ﬁbrotic
tissue [7,31]. However, the main limitation of MRI in the
very early posttreatment period (<2 months after
completion) is its difﬁculty distinguishing early
postradiation change from residual tumor, both of which
can demonstrate intermediate- to high-signal T2-weighted
intensity and avid gadolinium enhancement [33,34].
One retrospective study evaluating pelvic MRI at a
median of 5 weeks after completion of chemoradiation for
cervical cancer found that 37% (16 of 44) of MRI examinations were considered indeterminate for discriminating
residual disease and ﬁbrosis [34]. Despite diagnostic
conﬁdence in the remainder of cases, sensitivity and
speciﬁcity for residual disease were 80% and 55%,
respectively, indicating a high false-positive rate because of
posttreatment change. A more recent retrospective study in
cervical cancer patients found better performance of pelvic
MRI at a later postchemoradiation time point (median 9
weeks) with strict objective diagnostic criteria, achieving
sensitivity and speciﬁcity of 91% and 85%, respectively, for
residual disease [33]. Therefore, for cervical cancer, the
suggested time interval for determining posttherapy
treatment response with pelvic MRI is 3 to 6 months after
completion of therapy [27], although earlier imaging is
sometimes used for interim assessment of tumor regression
for prognostication and/or adaptive radiation planning.
Because MRI relies primarily on size criteria for nodal
evaluation, it has limitations similar to CT with respect to
sensitivity and speciﬁcity for nodal metastases. Therefore,
although MRI may depict size regression of nodal
metastases following therapy, it is likely at least modestly
inferior for detecting new or residual disease in
subcentimeter lymph nodes compared to FDG-PET/CT
[22,23,29,30].
If MRI of the abdomen and pelvis is used in place of CT
of the abdomen and pelvis, the addition of chest CT is
encouraged to evaluate for pulmonary metastases. The use of
IV contrast may improve tissue characterization and should
be used especially when MRI of the abdomen is included,
because it improves detection of hepatic metastases.
Journal of the American College of Radiology
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Radiography Intravenous Urography. There is no
relevant literature regarding the use of radiographic IV
urography in the modern imaging workup of vaginal cancer,
and its use has largely been replaced by cross-sectional imaging techniques.
US Abdomen and Pelvis Transabdominal. There is no
relevant literature regarding the role of TAUS in vaginal
cancer staging. TAUS is inferior for visualizing the female
genital tract compared with TVUS, and neither technique
has a role in nodal or distant evaluation.
US Pelvis Transvaginal. There is no relevant literature
regarding the role of TVUS in the early posttreatment
evaluation of primary vaginal cancer. Limited studies in
cervical cancer patients have evaluated the use of color and/
or power Doppler US for detecting changes in tumor
vascularity as a marker of treatment response [45]. However,
the applicability of these ﬁndings to clinical practice remains
unclear. The NCCN guidelines do not currently endorse
the use of TVUS for early posttreatment evaluation in
cervical cancer, and its role in vaginal cancer remains
undeﬁned. Additionally, TVUS has limited utility for
pelvic nodal evaluation [39].

Variant 3: Vaginal cancer. Suspected or
known recurrence. Evaluate extent of disease.
Initial imaging
Cross-sectional imaging plays a crucial role in the evaluation
of patients with known or suspected vaginal cancer recurrence, in which physical examination is of limited value in
determining disease extent. In one retrospective study of
patients with primary vaginal cancer who underwent
deﬁnitive radiation and experienced recurrence, the mechanism of recurrence was locoregional alone in 56% for
disease stages I and II and 71% for disease stages III to IVA,
whereas the remainder of recurrences were distant [46].
Once locoregional recurrence is identiﬁed, the presence or
absence of distant recurrence becomes a discriminating
factor in eligibility for salvage pelvic exenteration. In the
presence of distant recurrence, exenteration confers
morbidity without signiﬁcantly improving oncologic
outcomes, whereas in the absence of distant recurrence,
exenteration can potentially eradicate pelvic tumor burden.
When distant disease has been excluded by imaging and a
patient is deemed eligible for pelvic exenteration, the
degree of local organ invasion determines whether partial
(anterior or posterior) or total exenteration is indicated
[32]. Therefore, imaging ﬁndings in patients with known
or suspected vaginal cancer recurrence can inﬂuence both
the appropriateness and type of salvage therapy, in
addition to predicting prognosis.

CT Chest. Although thoracic metastases are known to
occur in vaginal cancer, no studies speciﬁcally address their
incidence or the incremental value of chest CT for suspected
recurrence. Pulmonary metastases have been studied to a
limited degree in cervical cancer, occurring in approximately
5% to 10% of patients at diagnosis [13,14]. Pulmonary
metastases appear to occur slightly more frequently as a
site of recurrent disease, with one large study of recurrent
cervical cancer indicating an overall incidence of 13% and
the lungs representing the only site of recurrence in 6% of
cases [15]. In studies evaluating pulmonary metastases
from cervical cancer, chest CT was the most frequent
diagnostic modality employed, with the vast majority of
patients asymptomatic at the time of imaging [16,17].
These ﬁndings support the use of chest CT with or
without IV contrast in the early posttreatment evaluation
of cervical cancer, as endorsed by the NCCN guidelines,
and suggest that a similar strategy would be useful for
vaginal cancer.
CT Abdomen and Pelvis. Data on the diagnostic performance of CT in known or suspected recurrence of vaginal
cancer are very limited, requiring extrapolation from pretreatment vaginal cancer cohorts as well as cohorts of patients with other gynecologic malignancies.
Regarding local extent evaluation, the prospective
ACRIN 6651 study of patients with cervical cancer prior to
treatment found that CT was insensitive for detection of
rectal and bladder invasion, suggesting that performance
would be similarly poor in the setting of recurrent disease
prior to pelvic exenteration [19].
A small retrospective study evaluating FDG-PET/CT in
23 patients with primary vaginal cancer prior to treatment
found that CT and FDG-PET detected pelvic nodal metastases in 17% (4 of 23) and 35% (8 of 23) of patients,
respectively, suggesting inferior sensitivity of CT alone for
nodal metastases. Although older literature suggested that
CT is less sensitive than PET/CT for nodal metastases [22],
the more recent ACRIN 6671/GOG 0233 trial in cervical
cancer patients prior to treatment showed a more modest
difference in sensitivity for abdominal nodes (42% versus
50%, respectively), and no signiﬁcant difference in
sensitivity for pelvic nodes (79% versus 83%, respectively)
[23]. Likewise, CT had only modestly lower AUC (0.83)
compared with PET/CT (0.90) for detection of nodal
metastases from cervical cancer in a recent meta-analysis
[24]. For distant metastases from cervical cancer, CT is
inferior in the detection of osseous metastases (sensitivity
66%) compared with FDG-PET/CT (sensitivity 96%) [25].
These ﬁndings, if applied to vaginal cancer, suggest that
CT is a reasonable staging tool for known or suspected tumor recurrence in the abdomen and pelvis, although it is
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likely inferior to MRI for evaluating local tumor extent,
modestly inferior to FDG-PET/CT for nodal metastases,
and inferior to FDG-PET/CT for osseous metastases. The
use of IV contrast is strongly encouraged when possible,
because the improved tissue contrast likely beneﬁts primary
tumor evaluation, delineation of lymph nodes from adjacent
vessels, and detection of hepatic metastases. No studies have
speciﬁcally assessed the performance of CT of the abdomen
and pelvis without IV contrast for evaluation of known or
suspected vaginal cancer recurrence.

FDG-PET/CT Skull Base to Mid-Thigh. No study has
evaluated FDG-PET/CT in a cohort limited to patients
with recurrent vaginal cancer. Data on the utility of FDGPET/CT in this setting is limited to mixed cohorts of
patients with various gynecologic malignancies, including
vaginal cancer, with cervical squamous cell carcinoma
generally comprising the majority of patients. One such
cohort of 27 patients with recurrent gynecologic malignancies prior to pelvic exenteration was studied prospectively to compare FDG-PET and CT. FDG-PET was 100%
sensitive and 73% speciﬁc for identifying extrapelvic metastases, most notably outperforming CT in the detection of
pelvic and para-aortic nodal metastases [29].
A retrospective study of 85 patients with recurrent gynecologic malignancies reached similar conclusions, identifying ﬁndings suspicious for extraregional recurrence in 28%
(24 of 85) of patients by PET versus 9% (8 of 85) of patients by conventional imaging (CT and pelvic MRI), with
nodal metastases accounting for many of the discrepancies
[30]. Concordant with these ﬁndings, the NCCN guidelines
recommend whole-body FDG-PET/CT in patients with
suspected recurrence of cervical cancer [27], although no
such formal guidelines exist for vaginal cancer.
FDG-PET/CT has also demonstrated the potential to
evaluate bladder, rectal, and pelvic sidewall invasion with
high accuracy (AUC 0.76-0.96) in patients with recurrent
gynecologic malignancies [47]. Nonetheless, MRI remains
the preferred modality for evaluating local tumor extent
for known or suspected vaginal cancer recurrence [32].
Fluoroscopy Contrast Enema. There is no relevant
literature regarding the use of ﬂuoroscopic contrast enema in
the modern imaging workup of vaginal cancer, and its use
has largely been replaced by cross-sectional imaging
techniques.
MRI Pelvis. Given the rarity of vaginal cancer, primary
data regarding the use of MRI in this setting are sparse.
Donati et al [32] evaluated the utility of pelvic MRI in 50
patients with recurrent or persistent pelvic malignancies
prior to pelvic exenteration, of which 12% (6 of 50) were
vaginal cancer and 56% (28 of 50) were cervical cancer.
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They compared all imaging ﬁndings to a surgical and
pathologic reference standard and found that for detection
of bladder, rectum, and pelvic sidewall invasion,
respectively, the AUC ranges for 2 readers were 0.95 to
0.96, 0.88 to 0.90, and 0.90 to 0.98; sensitivities were
87%, 75% to 81%, and 75% to 88%; and speciﬁcities
were 93% to 100%, 97%, and 94% to 97%, with
excellent interobserver agreement (k ¼ 0.81-0.85).
Although diagnostic performance in vaginal cancer was
not speciﬁcally separated, 68% (34 of 50) of the patients
had either vaginal or cervical cancer, therefore providing
some degree of generalizability to vaginal cancer patients.
Although MRI readily depicts lymph nodes, it has
constraints similar to CT with regard to the limited sensitivity and speciﬁcity of size and morphologic criteria. No
study has evaluated the diagnostic performance of MRI for
nodal staging isolated to a cohort of primary vaginal cancer
patients with disease recurrence. However, data from mixed
cohorts of patients with recurrence of cervical, vaginal, and
other gynecologic cancers have suggested superior sensitivity
of FDG-PET/CT for pelvic nodal metastases compared with
pelvic MRI and CT [29,30].
The use of IV contrast may improve tissue characterization but is not considered essential, with variable inclusion in published protocols for evaluation of vaginal [28,31]
and cervical cancer [7,32-34]. No study has speciﬁcally
compared the incremental utility of gadolinium-enhanced
sequences over T2-weighted sequences for pelvic MRI in
this context. Regarding the use of vaginal gel in MRI of the
pelvis, there is insufﬁcient primary data in the literature to
support its routine use.

MRI Abdomen and Pelvis. Given the rarity of vaginal
cancer, primary data regarding the use of MRI in this setting
are sparse. Donati et al [32] evaluated the utility of pelvic
MRI in 50 patients with recurrent or persistent pelvic
malignancies prior to pelvic exenteration, of which 12%
(6 of 50) were vaginal cancer and 56% (28 of 50) were
cervical cancer. They compared all imaging ﬁndings to a
surgical and pathologic reference standard and found that
for detection of bladder, rectum, and pelvic sidewall
invasion, respectively, the AUC ranges for 2 readers were
0.95 to 0.96, 0.88 to 0.90, and 0.90 to 0.98; sensitivities
were 87%, 75% to 81%, and 75% to 88%; and
speciﬁcities were 93% to 100%, 97%, and 94% to 97%,
with excellent interobserver agreement (k ¼ 0.81-0.85).
Although diagnostic performance in vaginal cancer was
not speciﬁcally separated, 68% (34 of 50) of the patients
had either vaginal or cervical cancer, therefore providing
some degree of generalizability to vaginal cancer patients.
Although MRI readily depicts lymph nodes, it has
constraints similar to CT with regard to the limited
Journal of the American College of Radiology
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sensitivity and speciﬁcity of size and morphologic criteria.
No study has evaluated the diagnostic performance of MRI
for nodal staging isolated to a cohort of primary vaginal
cancer patients with disease recurrence. However, data from
mixed cohorts of patients with recurrence of cervical,
vaginal, and other gynecologic cancers have suggested superior sensitivity of FDG-PET/CT for pelvic nodal metastases compared with pelvic MRI and CT [29,30].
If MRI of the abdomen and pelvis is used in place of CT
of the abdomen and pelvis, the addition of chest CT is
encouraged to evaluate for pulmonary metastases. The use of
IV contrast may improve tissue characterization and is
particularly beneﬁcial when MRI of the abdomen is included,
because it improves detection of hepatic metastases.

Radiography Intravenous Urography. There is no
relevant literature regarding the use of radiographic IV
urography in the modern imaging workup of vaginal cancer,
and its use has largely been replaced by cross-sectional imaging techniques.
US Pelvis Transvaginal. There is no relevant literature
regarding the role of TVUS in the evaluation of known or
suspected vaginal cancer recurrence nor is there any such
literature for cervical cancer recurrence. Additionally, the
potential applicability of TVUS for recurrent vaginal cancer
would be limited to local recurrence, because TVUS has
little to no utility for pelvic nodal evaluation [39].
US Abdomen and Pelvis Transabdominal. There is no
relevant literature regarding the role of TAUS in vaginal
cancer staging. TAUS is inferior for visualizing the female
genital tract compared with TVUS, and neither technique
has a role in nodal or distant evaluation.

SUMMARY OF RECOMMENDATIONS
n Variant

1: MRI pelvis without and with IV contrast or
CT abdomen and pelvis with IV contrast or FDGPET/CT skull base to mid-thigh is usually appropriate as the initial imaging for pretreatment staging of
vaginal cancer. These procedures are equivalent alternatives (ie, only one procedure will be ordered to
provide the clinical information to effectively manage
the patient’s care).

n Variant

3: MRI pelvis without and with IV contrast or
CT abdomen and pelvis with IV contrast or CT chest
with IV contrast or FDG-PET/CT skull base to midthigh is usually appropriate as the initial imaging of
vaginal cancer to evaluate the extent of disease with
suspected or known recurrence. These procedures are
equivalent alternatives (ie, only one procedure will be
ordered to provide the clinical information to effectively manage the patient’s care).

SUPPORTING DOCUMENTS
The evidence table, literature search, and appendix for this
topic are available at https://acsearch.acr.org/list. The appendix includes the strength of evidence assessment and the
ﬁnal rating round tabulations for each recommendation.
For additional information on the Appropriateness
Criteria methodology and other supporting documents go to
www.acr.org/ac.

RELATIVE RADIATION LEVEL INFORMATION
Potential adverse health effects associated with radiation
exposure are an important factor to consider when selecting
the appropriate imaging procedure. Because there is a wide
range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication
has been included for each imaging examination. The RRLs
are based on effective dose, which is a radiation dose
quantity that is used to estimate population total radiation
risk associated with an imaging procedure. Patients in the
pediatric age group are at inherently higher risk from
exposure, because of both organ sensitivity and longer life
expectancy (relevant to the long latency that appears to
accompany radiation exposure). For these reasons, the RRL
dose estimate ranges for pediatric examinations are lower as
compared with those speciﬁed for adults (see Table 2).
Additional information regarding radiation dose
assessment for imaging examinations can be found in the
ACR Appropriateness Criteria Radiation Dose
Assessment Introduction document [48].
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